Therapeutic Breakthroughs in Multiple Sclerosis, 2017 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Therapeutic
Breakthroughs in Multiple Sclerosis”
report to their offering.

This edition of the Future Tech TOE primarily encompasses comprehensive
analyses of key emerging therapies across multiple sclerosis (MS). The
service also includes treatment overviews, clinical pipeline analysis,
IP and funding analysis, and emerging innovations across MS therapies.
Furthermore, the research features the impact of key technology drivers
and restraints for the global MS therapeutic industry, while providing
an overview of the emerging technological landscape for MS treatments.

The Future Tech TechVision Opportunity Engine (TOE) captures emerging
innovations in research and development, or profile existing
technologies which have seen a resurgence in terms of new markets and
applications. It usually provides a technology overview, drivers,
challenges, research and development, analyst insights and key patent
information. In some cases, technology convergence scenarios and future
growth opportunities are outlined. It covers innovations and
technologies in a variety of industry spaces including manufacturing,
sensors, electronics, information and communications technologies,
networks, lighting technologies, healthcare, medical devices, materials
and coatings, and developments in the energy sector that contribute
toward a sustainable and greener world.

The Health & Wellness cluster tracks developments in a myriad of areas
including genetic engineering, regenerative medicine, drug discovery and
development, nanomedicine, nutrition, cosmetic procedures, pain and
disease management and therapies, drug delivery, personalized medicine,
and smart healthcare.

Key Topics Covered:

1. Overview of Multiple Sclerosis Treatments

1.1 New Therapies on the Horizon for Multiple Sclerosis

1.2 Summary of Existing Disease Modifying MS Therapies

1.3 Overview of Emerging MS Therapies

1.4 Role of Stem Cell Therapy in MS Management

1.5 Clinical Pipeline Overview for Late Phase MS Therapies

1.6 Clinical Pipeline Overview for Early Phase MS Therapies

2. Innovation Tracker

2.1 Breakthrough Approval for Roche’s Ocrelizumab

2.2 Novartis’s MS Portfolio Expands with Ofatumumab Acquisition

2.3 Evaluating Oral Biotin Formulation for Progressive MS

2.4 Role of Tyrosine Kinase Inhibitor in Progressive MS

2.5 Hematopoietic Stem Cell Therapy for MS Management

2.6 Antibody Therapy for Myelin Repair

3. Impact Analysis and Assessment

3.1 Summary of Key Technology Drivers and Restraints

3.2 Growing Demand for Targeted Therapies Likely to Fuel New Discoveries
across MS Management

3.3 High Risk of Treatment Toxicity Still a Major Concern across MS

4. Strategic Insights and Future Perspectives

4.1 US Leads the Global IP Landscape for MS Treatments

4.2 Analysis of Research Funding for MS Treatments in the US

4.3 DMTs Likely to Enhance the Future of MS Management

5. Appendix

For more information about this report visit


Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Topics: Central
Nervous System Drugs